



For immediate release
October 27, 2014

**MBC PHARMA INC. AND OSTEROS BIOMEDICA LTD. ANNOUNCE INITIATION OF A PHASE I
CLINICAL TRIAL OF MBC-11 IN PATIENTS WITH CANCER INDUCED BONE DISEASE**

*Aurora, CO, USA—October 27, 2014—*MBC Pharma Inc. and Maxwell Biotech Venture Fund's joint venture company Osteros Biomedica Ltd. announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease. The open-label dose-escalation trial investigates safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses MBC-11. Imaging, bone turnover and tumor specific biomarkers and pain assessment will be used to evaluate tumor response and therapeutic effect. Eighteen patients with established bone lesions from any cancer type will be enrolled in the study—predisposition to skeletal metastases in cancers such breast, prostate and multiple myeloma are anticipated to predominate patient enrollment.

Ekaterina Ivanova, Chief Executive Officer at Osteros Biomedica stated: "The patients in this trial are anticipated to benefit from the tissue targeting properties and the combined drug activities of the two known drugs from which MBC-11 is made. We are happy to bring this first-in-class compound into clinical testing in an area of high unmet need."

Alexander Karpeisky, President of MBC Pharma and Scientific Advisor of Osteros Biomedica commented, "We are excited to see the initiation of this trial and hope the pre-clinical observations of bone targeted anti-cancer efficacy, anti-resorptive activity and a good safety profile translate to the clinic".

Shawn Zinnen, Chief Executive Officer at MBC Pharma stated: " We have been very pleased with the committed working relationship with our partners at Osteros and the start of this study. And we are eager to see the results of this trial to establish human proof-of-concept of our novel approach to bone targeted therapeutics"

MBC-11 is the lead compound from a technology platform based on bisphosphonate driven bone targeted delivery of chemotherapy agents. MBC-11 is a synthetic chemical conjugate of a bone-targeting vehicle (Etidronate) and an anti-cancer agent (Cytarabine). It is designed to target malignant bone lesions and enables higher concentrations of drug at the sites of tumor-associated bone destruction than is otherwise possible; and may reduce systemic toxicity.

About Maxwell Biotech Group

Maxwell Biotech Group (MBG) and Maxwell Biotech Venture Fund, formed with the participation of Russian Venture Company, provide investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. MBG relies on an experienced international team of managers and financial and industry experts and has offices in Moscow and Boston.

About Osteros Biomedica

Osteros Biomedica, Ltd is a private Russian biotech company founded in 2012, and part of the biotech holding company, Maxwell Biotech Group. The Company's main goal is to develop and commercialize innovative drugs for the treatment of cancer-induced bone disease. The company has the global rights to its first product, MBC-11.

About MBC Pharma Inc

MBC Pharma, Inc. is a private pharmaceutical company developing small molecule drugs for critical bone, oncological and viral diseases. MBC Pharma drug discovery programs are built upon proprietary bone-targeting and other tissue targeting technologies. For information please contact: Shawn Zinnen, Tel.: +1(720) 859-4040, E-mail:

szinnen@mbcpharma.com